Immuno oncology News and Research

RSS

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), appointing John Lambert as Chair, with Morris Rosenberg and Peter de Waele serving alongside.

From VALANX Biotech 15 Apr 2026

Alligator Bioscience provides an update on mitazalimab

Alligator Bioscience, a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today provided a brief update regarding mitazalimab.

From Alligator Bioscience 11 Apr 2026

Bruker advances Functional Proteomics 2.0 with timsOmni™ mass spectrometry proteoform analysis for deeper insights into disease biology

Bruker Corporation today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants.

From Bruker Daltonics 24 Feb 2026

Senescent neutrophils promote tumor survival across cancer types

Renowned as first responders to threatening infections, neutrophils also happen to feature prominently in the microenvironment of tumors, where they and other immune cells play opposing and frequently mutable roles in promoting-or resisting-cancer progression.

6 Feb 2026

Bacterial metabolite enhances immune checkpoint therapy against lung cancer

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a drug for testing in humans.

14 Jan 2026

Elevated bacteria levels in tumors weaken immune response, studies show

Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why immunotherapy works for some patients but not others.

2 Jan 2026

Carolina Molecular partners with Pixelgen, becomes first US certified service provider for Pixelgen Proxiome Kit - Pixelgen Technologies

Carolina Molecular Inc., a leading molecular testing services laboratory, and Pixelgen Technologies AB announced today a partnership to expand access to cutting-edge 3D protein interactomics capabilities to researchers and clinicians in the United States. Carolina Molecular will be the first certified U.S. service provider for Pixelgen.

13 Nov 2025

Engineered biomaterial promotes formation of cancer-fighting immune cell clusters

Researchers at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of tertiary lymphoid-like structures, or TLSs.

6 Nov 2025

Mitochondria and lysosomes work together to control regulatory T cell activation

Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the immune system.

24 Oct 2025

Age alone may not predict outcomes in acute myeloid leukemia

An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group reveals that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic.

14 Oct 2025

PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies

PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP manufacturing, aiming to accelerate non-viral cell and gene therapies for the benefit of patients.

From PlasmidFactory GmbH 9 Oct 2025

Nanomedicine emerges as a key tool to boost cancer immunotherapy

Scientists at the Fralin Biomedical Research Institute at VTC and their collaborators are exploring emerging trends in cancer immunotherapy, with back-to-back review articles published in Nature Cancer and Trends in Cancer that look at how nanotechnology could reprogram the immune system and help overcome tumors' defenses.

8 Oct 2025

Combination immunotherapy prior to surgery shows encouraging results in mesothelioma

Results from an early phase clinical trial presented this week at the World Conference on Lung Cancer Meeting in Barcelona, Spain, and published in the Nature Medicine journal today [Monday, 8th September 2025] show that patients with mesothelioma - a rare cancer of the lining of the lung that may be caused by exposure to asbestos - who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery had successful surgeries and encouraging early outcomes.

9 Sep 2025

Novel insights from lymphoid structures: Lessons from colorectal cancer research

Discover how lymphoid structures and germinal centers provide powerful prognostic insights into colorectal cancer.

From TissueGnostics 31 Jul 2025

New mRNA vaccine strategy awakens immune system to fight cancer

An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to "wake up" the immune system against cancer.

18 Jul 2025

Updated NeoVax cancer vaccine shows improved immune response in melanoma trial

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform.

10 Jul 2025

OCCAM Immune and Cancer Research Institute join forces to advance immunotherapy

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on understanding the immune system's role in disease-is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies.

17 Jun 2025

Mitochondrial DNA variant predicts resistance to melanoma immunotherapy

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do not respond to the latest cancer treatments.

6 Jun 2025

Genetic mutation identified as key factor in immunotherapy resistance for melanoma

Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune checkpoint inhibitors.

5 Jun 2025